Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Sep 5:2022:4853481.
doi: 10.1155/2022/4853481. eCollection 2022.

Analysis of the Relationship between Scleritis and T Cell Activation in Patients with Hepatocellular Carcinoma Treated with PD-1 Carrelizumab

Yazhen Yuan  1 , Shuaixi Pan  2 , Changpeng Zou  3 , Yan Guo  3 , Changwang Zhang  3 , Zheng Zheng  3 , Ninghan Wu  4 , Na Li  3
Affiliations

Analysis of the Relationship between Scleritis and T Cell Activation in Patients with Hepatocellular Carcinoma Treated with PD-1 Carrelizumab

Yazhen Yuan et al. Contrast Media Mol Imaging. .

Retraction in

Abstract

In order to explore the function of inhibiting the immune effect, the relationship between programmed death receptor 1 (PD-1) carrelizumab in the treatment of hepatocellular carcinoma-induced scleritis and T cell activation is investigated. A total of 120 patients with primary liver cancer treated in the department of oncology of our hospital from July 2020 to January 2022 are selected and treated with carrelizumab. According to the occurrence of PD-1 carrelizumab treatment, the patients are divided into the scleritis group and nonscleritis group. The levels of T cells, PD-1, PD-L1 proteins, and serum inflammatory factors at different time points are compared. The experimental results show that the occurrence of scleritis after liver cancer treatment with PD-1 carrelizumab is closely associated with Treg cells, the percentage of Th17 cells, the expression of PD-1, PD-L1 proteins, and inflammatory factors. It is clearly evident that PD-1 carrelizumab can increase the risk of scleritis by affecting T cell activation.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Figures

Figure 1
Figure 1
Percentage changes of Treg cells and Th17 cells.
Figure 2
Figure 2
Protein expression differences between PD-1 and PD-L1.
Figure 3
Figure 3
Changes in the expression of inflammatory factors.
See this image and copyright information in PMC

References

    1. Beyer A. M., Bonini M. G., Moslehi J. Cancer therapy-induced cardiovascular toxicity: old/new problems and old drugs. American Journal of Physiology - Heart and Circulatory Physiology . 2019;317(1):164–167. doi: 10.1152/ajpheart.00277.2019. - DOI - PMC - PubMed
    1. Xia L., Liu Y., Wang Y. PD-1/PD-L1 blockade therapy in advanced non-small-cell lung cancer:current status and future directions. The Oncologist . 2019;24(S1):S31–S41. doi: 10.1634/theoncologist.2019-io-s1-s05. - DOI - PMC - PubMed
    1. Khunger A., Battel L., Wadhawan A., More A., Kapoor A., Agrawal N. New insights into mechanisms of immune checkpoint inhibitor-induced cardiovascular toxicity. Current Oncology Reports . 2020;22(7):65. doi: 10.1007/s11912-020-00925-8. - DOI - PubMed
    1. National Health Commission of Prc. Guidelines for the diagnosis and treatment of primary liver cancer (2022 edition) Chin J Dis . 2022;35(1)
    1. Wu Y., Lin L., Liu X. Identification of PDL1-related biomarkers to select lung adenocarcinoma patients for PD1/PDL1 inhibitors. Disease Markers . 2020;2020:1–11. doi: 10.1155/2020/7291586. - DOI - PMC - PubMed

Publication types

MeSH terms